Get started
Author

Maria Cecilia Franco-Vega

Observed names: M.C. Franco-Vega, MARIA FRANCO VEGA, Maria C Franco Vega, Maria C. Franco Vega, Maria C. Franco-Vega, Maria Franco Vega, Maria Franco-Vega
ORCID: 0000-0001-6890-6130
Observed ORCID: 0000-0001-6890-6130
OpenAlex ID: A5072058971
Quality improvement project: Implementation of I-PASS, a structured patient hand-off tool to improve communication, increase patient safety, and prevent burnout among palliative care providers at a comprehensive cancer center.
2022 · Jaya Sheela Amaram-Davila, Holly A. Stewart, et al. · Journal of Clinical Oncology · 24
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report
2025 · Bingnan Zhang, Komal B. Shah, et al. · Journal of Thoracic Oncology · 22
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
2023 · M. Altan, F. Soto, et al. · Clinical Oncology · 22
Enhancing Implementation of the I-PASS Handoff Tool Using a Provider Handoff Task Force at a Comprehensive Cancer Center
2024 · Maria C. Franco Vega, Mohamed Ait Aiss, et al. · The Joint Commission Journal on Quality and Patient Safety · 13
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis
2024 · Felipe Soto-Lanza, Lydia Glick, et al. · Clinical Lung Cancer · 10
Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.
2025 · Mitchell Parma, Eric Kumar Singhi, et al. · Journal of Clinical Oncology · 7
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events
2023 · Mehmet Altan, Quan-Zhen Li, et al. · Frontiers in Immunology · 6
PDF
Improving handoff with the implementation of I-PASS at a tertiary oncology hospital
2023 · Maria C Franco Vega, Mohamed Ait Aiss, et al. · BMJ Open Quality · 6
PDF
Optimizing inpatient care for lung cancer patients with immune checkpoint inhibitor-related pneumonitis using a clinical care pathway algorithm
2024 · Norman Brito-Dellan, Maria Cecilia Franco-Vega, et al. · Supportive Care in Cancer · 5
PDF
Perceptions Toward Naloxone Among Patients With Cancer Receiving Opioids
2024 · Jaya Amaram-Davila, Maria Franco Vega, et al. · Journal of Pain and Symptom Management · 5
PDF
A case of Creutzfeldt-Jakob disease following cataract surgery: sporadic versus iatrogenic cause.
2013 · Rosana Gnanajothy, Devika Umashanker, et al. · PubMed · 5
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS
2025 · Bingnan Zhang, Laura Alder, et al. · Lung Cancer · 4
Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center
2024 · Malek Shatila, Farzin Eshaghi, et al. · Cancers · 4
PDF
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
2026 · Mitchell Parma, Kaiwen Wang, et al. · JCO Precision Oncology · 2
Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service
2024 · Joanna-Grace M. Manzano, Hadeel Sahar, et al. · Supportive Care in Cancer · 2
From Emails to EMR: Implementing I-PASS Among Inpatient Palliative Care Clinicians at a Comprehensive Cancer Center—A Quality Improvement Initiative
2025 · Jaya Amaram-Davila, Maria Franco Vega, et al. · Cancers · 1
PDF
Using I-PASS to improve nursing handoffs across the continuum of care at a tertiary oncology hospital
2025 · Mohamed Ait Aiss, Delmy Vesho, et al. · BMJ Open Quality · 1
PDF
Clinical characteristics and outcomes of cancer patients with chronic kidney disease and coronavirus disease 2019.
2021 · Omar Mamlouk, Anastasia Turin, et al. · Journal of Clinical Oncology · 1
Acute kidney injury and major outcomes in cancer patients with no history of chronic kidney disease (CKD) with coronavirus 2019 (COVID-19) infection.
2021 · Cesar Simbaqueba, Omar Mamlouk, et al. · Journal of Clinical Oncology · 1
Risk factors of developing multisystem immunotherapy-related adverse events among patients with breast cancer treated with immune checkpoint inhibitors.
2025 · Ashwathy Balachandran Pillai, Nazia Sadiq, et al. · Journal of Clinical Oncology
1182 Multisystem immunotherapy-related adverse events among patients with breast cancer treated with immune checkpoint inhibitors
2024 · Ashwathy Balachandran Pillai, Nazia Sadiq, et al. · Regular and Young Investigator Award Abstracts
CLO24-066: Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non–Small Cell Lung Cancer: Risk Factors Associated With Mortality
2024 · Cesar Simbaqueba Clavijo, Mehmet Altan, et al. · Journal of the National Comprehensive Cancer Network
Wcn24-1364 Chronic Kidney Disease Impact on Coronavirus (covid-19) Infection Severity and Outcomes in Cancer Patients
2024 · Cesar Simbaqueba Clavijo, Omar Mamlouk, et al. · Kidney International Reports
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis
2024 · Felipe Soto, Lydia Glick, et al. · SSRN Electronic Journal
Factors Associated With One-year Survival Among Patients With Non-small Cell Lung Cancer Who Develop Immune Checkpoint Inhibitor Pneumonitis
2023 · LYDIA GLICK, FELIPE SOTO, et al. · CHEST Journal
PDF
Works count: 27
Citation count: 141
H-index: 6
I10-index: 5
Year
Topic
Type